PTC Therapeutics (NASDAQ: PTCT) reported Q2 EPS of ($1.14), $0.13 better than the analyst estimate of ($1.27). Revenue for the quarter came in at $15.6 million versus the consensus estimate of $14.68 million.

2016 Guidance:

• Total ex-U.S. Translarna nmDMD revenues for 2016 are anticipated to be between $65 and $85 million. This guidance assumes current exchange rates and the continued commercial expansion for Translarna in nmDMD outside of the U.S.
• Operating expenses for the full year 2016 are anticipated to be between $185 million and $195 million, excluding expected non-cash stock-based compensation expense of approximately $40 million, for total operating expenses of approximately $225 million to $235 million. These expenses will be primarily in support of our ongoing clinical trials for Translarna in nmDMD and nmCF, commercial launch activities for Translarna outside of the US, and the continued research and clinical development of other product pipeline candidates.
• PTC expects to end 2016 with cash and cash equivalents over $200 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.